Catalent Inc (NYSE:CTLT) SVP Lance Miyamoto sold 6,525 shares of the business’s stock in a transaction dated Tuesday, October 16th. The shares were sold at an average price of $42.50, for a total value of $277,312.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
CTLT stock opened at $41.37 on Friday. Catalent Inc has a 1-year low of $36.73 and a 1-year high of $47.87. The company has a market capitalization of $6.12 billion, a PE ratio of 26.02, a P/E/G ratio of 2.51 and a beta of 1.41. The company has a debt-to-equity ratio of 2.44, a quick ratio of 1.79 and a current ratio of 2.15.
Catalent (NYSE:CTLT) last released its quarterly earnings data on Tuesday, August 28th. The company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.06. Catalent had a return on equity of 20.42% and a net margin of 3.39%. The company had revenue of $685.30 million for the quarter, compared to analyst estimates of $690.69 million. During the same period in the prior year, the company posted $0.65 EPS. The company’s revenue was up 11.1% compared to the same quarter last year. Analysts forecast that Catalent Inc will post 1.72 earnings per share for the current year.
CTLT has been the topic of several research reports. Zacks Investment Research upgraded Catalent from a “hold” rating to a “buy” rating and set a $48.00 price target on the stock in a research note on Monday, July 9th. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a research note on Tuesday, June 26th. UBS Group initiated coverage on Catalent in a research note on Tuesday, October 9th. They set a “neutral” rating and a $48.00 price target on the stock. Finally, JPMorgan Chase & Co. boosted their price target on Catalent from $50.00 to $55.00 and gave the company an “overweight” rating in a research note on Wednesday, August 29th. Six equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Catalent has a consensus rating of “Buy” and an average price target of $49.33.
Several hedge funds have recently added to or reduced their stakes in CTLT. Seven Eight Capital LP bought a new stake in Catalent during the 3rd quarter worth approximately $506,000. Oakbrook Investments LLC grew its position in Catalent by 45.1% during the 3rd quarter. Oakbrook Investments LLC now owns 18,650 shares of the company’s stock worth $850,000 after acquiring an additional 5,800 shares during the last quarter. Aperio Group LLC grew its position in Catalent by 7.0% during the 3rd quarter. Aperio Group LLC now owns 33,563 shares of the company’s stock worth $1,529,000 after acquiring an additional 2,185 shares during the last quarter. Louisiana State Employees Retirement System grew its position in Catalent by 10.3% during the 3rd quarter. Louisiana State Employees Retirement System now owns 39,700 shares of the company’s stock worth $1,808,000 after acquiring an additional 3,700 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its position in Catalent by 1,327.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 16,413 shares of the company’s stock worth $748,000 after acquiring an additional 15,263 shares during the last quarter. Institutional investors own 91.76% of the company’s stock.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
See Also: What are the Different Types of Leveraged Buyouts?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.